Amylyx Pharmaceuticals, Inc. (AMLX) Financial Statements
Amylyx Pharmaceuticals, Inc. (AMLX) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$152.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$126.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AMLXAmylyx Pharmaceuticals, Inc.Follow AMLX — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Revenue | 22.2 | 380.8 | 87.4 | 0.0 | — | |
| Gross profit | 19.2 | 355.3 | 81.4 | 0.0 | — | |
| Research & development | 93.5 | 128.2 | 104.1 | 90.4 | 92.4 | |
| Operating income | -201.3 | 38.8 | -314.7 | -153.3 | -162.1 | |
| Pre-tax income | -197.6 | 54.3 | -302.1 | -144.7 | — | |
| Income tax | 0.8 | 5.0 | -0.4 | 0.0 | — | |
| Net income | -198.4 | 49.3 | -301.7 | -144.7 | -152.1 | |
| Diluted EPS ($) | -3.39 | 0.70 | -4.43 | -1.53 | -1.36 | |
| Diluted shares (mn) | 58.5 | 70.0 | 68.1 | 94.6 | — |
USD millions · SEC XBRL
Amylyx Pharmaceuticals, Inc. — questions
- What is Amylyx Pharmaceuticals, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Amylyx Pharmaceuticals, Inc.'s net income?
- -$152.1M over the twelve months to 2026-06-30.
- What is Amylyx Pharmaceuticals, Inc.'s free cash flow?
- -$126.7M over the twelve months to 2026-06-30.
- What are Amylyx Pharmaceuticals, Inc.'s diluted earnings per share?
- $-1.36 over the twelve months to 2026-06-30.
Every figure on this page comes from Amylyx Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.